Recombinant protein for treating myocardial hypertrophy and application thereof to preparation of medicine for resisting myocardial hypertrophy

A technology of cardiac hypertrophy and recombinant protein, applied in the field of medicine, can solve the problems such as the anti-cardiac hypertrophy effect of galectin 1 that has not been reported, and achieve the improvement of intracellular calcium and calcium-related signal protein disorders, improve signal pathways, and inhibit expression Effect

Inactive Publication Date: 2018-10-26
NANJING MEDICAL UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the role of galectin-1 in the preparation of anti-cardiac hypertrophy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant protein for treating myocardial hypertrophy and application thereof to preparation of medicine for resisting myocardial hypertrophy
  • Recombinant protein for treating myocardial hypertrophy and application thereof to preparation of medicine for resisting myocardial hypertrophy
  • Recombinant protein for treating myocardial hypertrophy and application thereof to preparation of medicine for resisting myocardial hypertrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Production of hypertrophic cardiomyocyte model

[0032] (1) Isolation of neonatal rat ventricular myocytes (NRVMs): SD neonatal rats within 48 hours of birth were collected regardless of sex. The heart tissue was excised and placed in ice water bath containing Ca 2+ , Mg 2+ Hanks' Balanced Salt Solution (HBSS, Gibco, Thermo Fisher). The blood in the heart chamber was washed away with HBSS, and the non-myocardial tissue was removed under the microscope using a stereo microscope. Carefully cut the myocardial tissue into a uniform size, about 1mm, with curved scissors in a sterile centrifuge tube 3 tissue fragments. Myocardial tissue was digested with an enzyme complex containing 0.06% trypsin (Sigma-Aldrich, Merck) and 0.04% type II collagenase (Sigma-Aldrich, Merck), formulated in calcium- or magnesium-free HBSS solution. After several times of digestion at 37°C, cardiomyocytes were obtained. Cardiac fibroblasts were removed by differential attachment for 1 hour, a...

Embodiment 2

[0035] Determination of surface area and membrane capacitance of cardiomyocytes

[0036] (1) Using anti-α-actinin antibody (1:100 dilution) to perform immunofluorescence staining on cardiomyocytes treated with galectin 1, and scan cell fluorescence pictures under a confocal laser microscope (LSM710, Zeiss, Germany), the The obtained images were measured by Image J software (NIH) for cell surface area.

[0037] (2) Since the cell membrane capacitance represents the size of the cell, the present invention uses the patch clamp technique to measure the myocardial cell membrane capacitance after galectin-1 treatment. The formulation of the whole cell voltage clamp electrode external solution is as follows: (unit: mM) 140TEA-Cl, 10HEPES, 1MgCl 2 , 5CaCl 2 , 10glucose, pH 7.4, osmotic pressure 300-310mOsm / L. The inner solution of the electrode contains (unit: mM) 130CsCl, 5EGTA, 1MgCl 2 , 10HEPES, 2Na 2 ATP, 0.5GTP, 10glucose, pH 7.2, osmotic pressure 290-300mOsm / L. Use Axopatc...

Embodiment 3

[0039] Detection of intracellular calcium level in cardiomyocytes

[0040]The detection of intracellular calcium in cardiomyocytes uses the Fluo-4AM probe (Molecular Probe, ThermoFisher). The specific method is: the cardiomyocytes are planted in a cell culture dish pre-coated with laminin, and cultured in DMEM medium for 24 hours . After the cells adhered to the wall, the medium was replaced, and the cells were washed 3 times with bench-top solution. Tyrode solution contains: 140NaCl, 5.4KCl, 1.8CaCl 2 , 1MgCl 2 , 10HEPES, and 10glucose, the pH was adjusted to 7.4 with NaOH. Afterwards, Fluo-4AM fluorescent probe was added to make the final concentration 4 μM. After incubating at 37°C for 30 minutes, the cells were washed with Tyrode's solution to wash away excess dye. A laser confocal microscope (LSM710, Zeiss, Germany) was used for shooting, using the Time series continuous recording mode, the quality was 7, the sampling size was 512×512, and the scanning speed of each ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses recombinant protein for treating myocardial hypertrophy and application thereof to preparation of a medicine for resisting the myocardial hypertrophy. The recombinant protein for treating the myocardial hypertrophy is recombinant human galactose recognition protein; an amino acid sequence of the recombinant human galactose recognition protein is shown as SEQ ID No. 1. The recombinant human galactose recognition protein is galectin 1 (galectin-1). The galectin 1 disclosed by the invention can be used for alleviating the myocardial hypertrophy, improving calcium-related signal protein of hypertrophic myocardium internal derangement and inhibiting the expression of hypertrophic genes of myocardial cells.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a recombinant protein for treating cardiac hypertrophy and its application in the preparation of anti-cardiac hypertrophy drugs. Background technique [0002] Cardiac hypertrophy is a relatively common cardiomyopathy, whether in the world or in my country, usually caused by increased systolic afterload and excessive cardiac sympathetic excitement (such as hypertensive heart disease). Under physiological conditions, in order to meet the needs of the body, the increased work of the heart produces physiological myocardial hypertrophy, which is a compensatory mechanism, but if it continues to develop, it can transform into decompensated pathological myocardial hypertrophy, and eventually develop into heart failure. [0003] In my country, the incidence of heart failure caused by myocardial hypertrophy is relatively high. Due to insufficient heart function, patients with myocardial ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/47C12N15/12A61K38/17A61P9/00
CPCA61K38/00A61P9/00C07K14/4726
Inventor王觉进范文勇樊佳雷建震朱国庆
OwnerNANJING MEDICAL UNIV